APDN: Puntuación IA 46/100 — Análisis IA (Abr 2026)
Applied DNA Sciences, Inc. specializes in DNA-based solutions for diagnostics, drug development, supply chain security, and anti-counterfeiting. Their technologies include molecular tags, DNA readers, and COVID-19 diagnostic tests, serving diverse markets across the United States, Europe, and Asia.
Datos Clave:
Puntuacion AI: 46/100
Sector: Healthcare
Descripción general de la empresa
Resumen:
Applied DNA Sciences, Inc. specializes in DNA-based solutions for diagnostics, drug development, supply chain security, and anti-counterfeiting. Their technologies include molecular tags, DNA readers, and COVID-19 diagnostic tests, serving diverse markets across the United States, Europe, and Asia.
Applied DNA Sciences, Inc. leverages DNA technology for diagnostics, supply chain security, and anti-counterfeiting. Its key products include molecular tags, DNA readers, and COVID-19 diagnostic tests. The company operates in the medical diagnostics and supply chain security sectors, facing competition from established players and evolving regulatory landscapes.
¿Qué hace APDN?
Founded in 1983 and headquartered in Stony Brook, New York, Applied DNA Sciences, Inc. has evolved from its origins as Datalink Systems, Inc. to become a developer and marketer of DNA-based technology solutions. The company operates in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets, as well as providing supply chain security, anti-counterfeiting, and anti-theft technology. Applied DNA Sciences' product portfolio includes SigNature molecular tags, which are used to protect against counterfeiting and strengthen supply chain security. SigNify IF portable DNA readers and SigNify consumable reagent test kits provide real-time authentication of molecular tags in the field. The CertainT platform offers tagging, testing, and tracking solutions. The company also manufactures and sells the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test kit, and the safeCircle COVID-19 diagnostic test kit. Applied DNA Sciences also provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets, as well as contract research services to RNA based drug and biologic customers for preclinical studies. Additionally, the company is developing an invasive circulating tumor cell capture and identification technology. The company operates in the United States, Europe, Asia, and internationally.
¿Cuál es la tesis de inversión de APDN?
Applied DNA Sciences, Inc. presents a speculative investment opportunity within the medical diagnostics and supply chain security sectors. The company's diverse product offerings, including DNA-based diagnostics and anti-counterfeiting solutions, cater to growing markets. Key value drivers include the expansion of its COVID-19 testing services and the adoption of its supply chain security technologies. The company's gross margin stands at 23.1%. However, the company's negative P/E ratio of -0.22 and a significant negative profit margin of -1515.9% indicate financial challenges. Growth catalysts include potential partnerships and regulatory approvals. Potential risks include competition and the need for additional funding.
¿En qué industria opera APDN?
Applied DNA Sciences, Inc. operates in the competitive medical diagnostics and supply chain security industries. The medical diagnostics market is driven by technological advancements and increasing demand for rapid and accurate testing. The supply chain security market is growing due to rising concerns about counterfeiting and product integrity. Applied DNA Sciences competes with companies offering similar DNA-based solutions and traditional security measures. The company's success depends on its ability to innovate, secure partnerships, and navigate regulatory hurdles. Competitors include companies like AFMD, ARAV, AWH, BPTS, and DMTKQ.
Medical - Diagnostics & Research
Healthcare
¿Cuáles son las oportunidades de crecimiento de APDN?
- Growth opportunity 1: Expansion of COVID-19 Testing Services: Applied DNA Sciences can capitalize on the ongoing need for COVID-19 testing by expanding its LineaTM COVID-19 Assay Kit and safeCircle offerings. The global COVID-19 diagnostics market is expected to remain substantial, driven by new variants and the need for continuous monitoring. Success hinges on securing contracts with schools, workplaces, and communities, and adapting to evolving testing protocols. Timeline: Ongoing.
- Growth opportunity 2: Adoption of Supply Chain Security Solutions: The company's SigNature molecular tags and CertainT platform offer a unique value proposition for brands seeking to combat counterfeiting and ensure product authenticity. The global anti-counterfeiting packaging market is projected to reach billions of dollars. Key to success is demonstrating the effectiveness and cost-efficiency of its solutions to potential clients in various industries. Timeline: Ongoing.
- Growth opportunity 3: Development of Invasive Circulating Tumor Cell Technology: Applied DNA Sciences' research into capturing and identifying invasive circulating tumor cells presents a significant opportunity in the oncology diagnostics market. The market for liquid biopsy technologies is rapidly expanding. Success depends on clinical trial outcomes, regulatory approvals, and commercialization partnerships. Timeline: Future (dependent on research progress).
- Growth opportunity 4: Partnerships and Collaborations: Strategic alliances with pharmaceutical companies, diagnostic providers, and supply chain stakeholders can accelerate the adoption of Applied DNA Sciences' technologies. Collaborations can provide access to new markets, funding, and expertise. Identifying and securing mutually beneficial partnerships is crucial for growth. Timeline: Ongoing.
- Growth opportunity 5: Geographic Expansion: Applied DNA Sciences currently operates in the United States, Europe, and Asia. Expanding its geographic footprint to new markets can drive revenue growth. This requires adapting its products and services to local regulations and market needs. Identifying and prioritizing high-growth regions is essential. Timeline: Ongoing.
- Market capitalization of $0.01 billion, reflecting its small-cap status.
- Negative P/E ratio of -0.22, indicating the company is not currently profitable.
- Profit margin of -1515.9%, highlighting significant losses.
- Gross margin of 23.1%, demonstrating some profitability at the product level.
- Beta of 0.13, suggesting low volatility compared to the overall market.
¿Qué productos y servicios ofrece APDN?
- Develops and markets DNA-based technology solutions.
- Offers solutions for nucleic acid-based in vitro diagnostics.
- Provides preclinical nucleic-acid based drug development and manufacturing services.
- Offers supply chain security, anti-counterfeiting, and anti-theft technology.
- Manufactures and sells COVID-19 PCR-based molecular diagnostic test kits.
- Provides contract research services to RNA based drug and biologic customers.
- Develops technology for capturing and identifying invasive circulating tumor cells.
¿Cómo gana dinero APDN?
- Sells DNA-based technology solutions to various industries.
- Generates revenue from the sale of diagnostic test kits.
- Provides contract research and manufacturing services.
- Licenses its technology to partners.
- Pharmaceutical companies
- Diagnostic providers
- Supply chain stakeholders
- Brands seeking anti-counterfeiting solutions
- Proprietary DNA-based technology.
- Patented solutions for supply chain security and diagnostics.
- Established relationships with key customers.
- Expertise in DNA-based research and development.
¿Qué podría impulsar al alza las acciones de APDN?
- Upcoming: Potential FDA approvals for new diagnostic tests.
- Ongoing: Expansion of COVID-19 testing contracts.
- Ongoing: Adoption of supply chain security solutions by new customers.
- Upcoming: Results from clinical trials for invasive circulating tumor cell technology.
¿Cuáles son los riesgos clave de APDN?
- Potential: Competition from larger and more established companies.
- Potential: Regulatory hurdles and changing industry standards.
- Ongoing: Economic downturns and reduced healthcare spending.
- Potential: Technological obsolescence and the emergence of alternative solutions.
- Ongoing: Dependence on key customers and contracts.
¿Cuáles son las fortalezas clave de APDN?
- Proprietary DNA-based technology platform.
- Diverse product portfolio addressing multiple markets.
- Expertise in supply chain security and diagnostics.
- Established partnerships with key customers.
¿Cuáles son las debilidades de APDN?
- Negative profitability and high operating losses.
- Small market capitalization and limited financial resources.
- Dependence on key customers and contracts.
- Limited brand recognition compared to larger competitors.
¿Qué oportunidades tiene APDN?
- Expansion of COVID-19 testing services.
- Adoption of supply chain security solutions.
- Development of invasive circulating tumor cell technology.
- Strategic partnerships and collaborations.
¿A qué amenazas se enfrenta APDN?
- Competition from larger and more established companies.
- Regulatory hurdles and changing industry standards.
- Economic downturns and reduced healthcare spending.
- Technological obsolescence and the emergence of alternative solutions.
¿Quiénes son los competidores de APDN?
- Affimed N.V. — Focuses on cancer immunotherapy. — (AFMD)
- Aravive, Inc. — Develops therapeutics for oncology and fibrotic diseases. — (ARAV)
- Aspira Women's Health Inc. — Focuses on ovarian cancer diagnostics. — (AWH)
- Biophytis S.A. — Develops therapeutics for age-related macular degeneration and sarcopenia. — (BPTS)
- DMC Global Inc. — Provides technical products and services. — (DMTKQ)
Key Metrics
- MoonshotScore: 46/100
Company Profile
- CEO: James A. Hayward Sc.D.
- Headquarters: Stony Brook, US
- Employees: 46
- Founded: 2003
AI Insight
AI analysis pending for APDN
Preguntas y respuestas
What does Applied DNA Sciences, Inc. do?
Applied DNA Sciences, Inc. develops and commercializes DNA-based technology solutions for various industries, including diagnostics, drug development, and supply chain security. The company's core offerings include molecular tags for anti-counterfeiting, DNA readers for authentication, and COVID-19 diagnostic test kits. It also provides contract research and manufacturing services for nucleic acid-based therapeutics. The company aims to leverage its DNA technology platform to address critical challenges in healthcare and supply chain integrity, operating in the United States, Europe, and Asia.
What do analysts say about APDN stock?
AI analysis is pending for Applied DNA Sciences, Inc. Therefore, a comprehensive analyst consensus is not currently available. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, P/E ratio, profit margin, and growth prospects. Factors influencing the stock's performance include regulatory approvals, contract wins, and technological advancements.
What are the main risks for APDN?
Applied DNA Sciences, Inc. faces several risks, including intense competition from larger companies in the diagnostics and supply chain security markets. Regulatory hurdles and changing industry standards could impact the company's ability to commercialize its products. Economic downturns and reduced healthcare spending could also negatively affect revenue. Additionally, the company faces the risk of technological obsolescence and the emergence of alternative solutions. Dependence on key customers and contracts poses a concentration risk.